Sympazan (Clobazam) Patent Expiration, LOE Window & CMS Spending

Sympazan (Clobazam) by Cosette: FDA Orange Book LOE 2040-01-31, 17 AB generics, $14.3M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCosette
FDA Application & PathwayN210833 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-01-31
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors17
2024 CMS Total Public Spend$14.3M
2024 Medicare Part D Spend$2.6M
2024 Medicaid Spend$11.8M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 16.4% 2-yr change)